Senior Software Engineer, 23andMe

This access to genetic insight has helped the company sell more than 15 million test kits in the last 15 years. This remains the core component of the business. Access to millions of customers DNA however has given the company a vast collection of genetic material, allowing 23andMe to expanded into the drug development space where it is collaborating with pharmaceutical giant GlaxoSmithKline.

23andMe is not without competition, with other big names including Ancestry and MyHeritage. The company has faced challenges, from weak demand for kits and a failed subscription model to a data breach and bankruptcy. Still, its acquisition by Regeneron in 2025 gives it a fresh star and 23andMe will go on operating, contributing to medical research, while protecting user privacy.